New research reveals that people who stop using new slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a major health publication points out that while overweight people can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying these medications need to be aware of the danger of quick rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass in about a year and a half.
Weighing Approaches
The study, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually experience a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the way of the injections is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals argue that, considering the high risk of relapse, the treatment might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Individuals who have come off the jabs report a powerful resurgence of cravings.
"It was like a switch flipping and I was suddenly ravenous," recalled an individual.
This difficulty is compounded if individuals have not established lasting lifestyle or habit changes during therapy.
Widespread Use
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are effective tools for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle support.
